Update on Phase Three Clinical Trial for EPP Participants with Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) are needed!

  • Friday, April 3, 2020

We are writing with the exciting news that Mitsubishi Tanabe is announcing a Phase 3 trial for MT-7117 for patients with EPP.

The hard work of those who participated in the Phase 2 trial paved the way for this FIRST clinical trial that includes adolescents.

Trial Description: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, And Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Treatment: Oral medication (pills), once daily in the morning with or without food Duration: 26 weeks plus optional 26 week double-blinded extension.

Endpoint: Increased pain free light exposure in adults and adolescents with a history of phototoxic reactions from EPP or XLP.

Study Sites: There will be 12 study sites in the US, followed by global study sites across multiple countries.

Age Range: Patients age 12- 75 Travel will be included and will be arranged by a concierge service trained on EPP/XLP.

Please contact the American Porphyria Foundation for more information and we will connect you with a study site nearest you.

Email kristen@porphyriafoundation.org
OR call 866-APF-3635 301-347-7166